Hospital
Cuba Memorial Hospital, INC.
Cuba Memorial Hospital, INC. was paid $4.56M by Medicaid between Jul 2019 and Nov 2024, across 26 billing codes. Its largest line is 99282, Emergency department visit for the evaluation and management, low to moderate severity — 39% of everything it billed.
33Billing provider infoCUBA MEMORIAL HOSPITAL, INC.
CUBA, NY 14727
CUBA, NY 14727
33aNPI1407839822assigned 11/21/2005
33bProvider typeGeneral Acute Care Hospital
28Total paid$4.56M
24GClaims27,392
24DCodes billed26
24AFirst – last monthJul 2019 – Nov 2024
Compared with peers
Next to other General Acute Care Hospital providers in New York
Rank by total paid#97 of 231
Median peer was paid$561K
This provider vs. median8.1×
Peers share this provider's primary NPPES type and state. Size alone says nothing about billing quality: a big agency or a hospital system is expected to sit far above the median.
Box 24A · Dates of service
Paid by month
Paid that monthNov–Dec 2024: claims still arriving when the file was cut, so these months run low for every provider
By year, as a table
| Year | Claims | Paid | |
|---|---|---|---|
| 2019 | 1,831 | $151K | |
| 2020 | 2,754 | $237K | |
| 2021 | 3,646 | $371K | |
| 2022 | 5,989 | $1.80M | |
| 2023 | 8,526 | $1.39M | |
| 2024incomplete | 4,646 | $615K |
Box 24 · Service lines
What it billed for
| Code | Service | Share | Claims | Bene. records | Paid |
|---|---|---|---|---|---|
| 99282 | Emergency department visit for the evaluation and management, low to moderate severity | 39% | 6,548 | 6,311 | $1.76M |
| 99283 | Emergency room visit (moderate)Emergency department visit for the evaluation and management, moderate severity | 31% | 5,944 | 5,717 | $1.41M |
| 99212 | Office or other outpatient visit for the evaluation and management of an established patient, straightforward | 14% | 1,981 | 1,891 | $621K |
| 99213 | Doctor's office visit, returning patient (routine)Office or other outpatient visit for the evaluation and management of an established patient, low complexity | 5.4% | 3,755 | 1,879 | $247K |
| 87070 | 3.4% | 1,618 | 1,599 | $154K | |
| 81002 | 1.8% | 1,294 | 1,276 | $80K | |
| 96372 | Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular | 1.6% | 463 | 456 | $73K |
| 87880 | Infectious agent antigen detection by immunoassay; Streptococcus, group A | 1.3% | 1,917 | 1,893 | $61K |
| 87804 | Infectious agent antigen detection by immunoassay; Influenza, each type | <1% | 596 | 590 | $43K |
| 71046 | Radiologic examination, chest; 2 views | <1% | 534 | 527 | $39K |
| 99284 | Emergency room visit (serious)Emergency department visit for the evaluation and management, high severity | <1% | 63 | 63 | $15K |
| 81025 | <1% | 293 | 289 | $12K |
14 more codes
| U0003 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, making use of high throughput technologies as described by cms-2020-01-r | <1% | 157 | $10K |
| 99281 | Emergency department visit for the evaluation and management, self-limited or minor | <1% | 51 | $7K |
| 87807 | <1% | 238 | $5K | |
| 73630 | <1% | 40 | $5K | |
| 73610 | <1% | 39 | $3K | |
| 87635 | Infectious agent detection by nucleic acid; SARS-CoV-2 (COVID-19), amplified probe | <1% | 42 | $2K |
| 87086 | Culture, bacterial; quantitative colony count, urine | <1% | 721 | $2K |
| 94640 | Pressurized or nonpressurized inhalation treatment for acute airway obstruction | <1% | 162 | $758.52 |
| 74019 | <1% | 13 | $506.00 | |
| 87088 | <1% | 467 | $364.87 | |
| 87276 | <1% | 119 | $216.60 | |
| 87275 | <1% | 119 | $216.60 | |
| 93005 | Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report | <1% | 25 | $90.23 |
| J1885 | Injection, ketorolac tromethamine, per 15 mg | <1% | 193 | $43.33 |
Claims and beneficiary counts add up across code × month rows, so one patient seen every month counts many times. Rows with fewer than 12 claims are suppressed by HHS, so small lines can be missing.
From NPPES
Who's on the registration
Authorized officialKERLING, NORMA (CEO)